about
Medical physics aspects of the synchrotron radiation therapies: Microbeam radiation therapy (MRT) and synchrotron stereotactic radiotherapy (SSRT)In situ biological dose mapping estimates the radiation burden delivered to 'spared' tissue between synchrotron X-ray microbeam radiotherapy tracks.Benchmarking and validation of a Geant4-SHADOW Monte Carlo simulation for dose calculations in microbeam radiation therapy.An evaluation of dose equivalence between synchrotron microbeam radiation therapy and conventional broad beam radiation using clonogenic and cell impedance assays.DNA damage and repair kinetics after microbeam radiation therapy emulation in living cells using monoenergetic synchrotron X-ray microbeams.Eosinophil-Associated Gene Pathways but not Eosinophil Numbers are Differentially Regulated between Synchrotron Microbeam Radiation Treatment and Synchrotron Broad-Beam Treatment by 48 Hours Postirradiation.In vitro study of genes and molecular pathways differentially regulated by synchrotron microbeam radiotherapy.Genome-wide transcription responses to synchrotron microbeam radiotherapy.Microbeam-irradiated tumour tissue possesses a different infrared absorbance profile compared to broad beam and sham-irradiated tissue.Reference dosimetry at the Australian Synchrotron's imaging and medical beamline using free-air ionization chamber measurements and theoretical predictions of air kerma rate and half value layer.Memory and survival after microbeam radiation therapy.High spatial resolution dosimetric response maps for radiotherapy ionization chambers measured using kilovoltage synchrotron radiation.Energy spectra considerations for synchrotron radiotherapy trials on the ID17 bio-medical beamline at the European Synchrotron Radiation Facility.Pre-treatment verification of intensity modulated radiation therapy plans using a commercial electronic portal dosimetry system
P50
Q28082894-2D8AF431-C32F-4D84-BCF8-99D79640E2ADQ34125308-342749C5-8E13-4974-A2CA-3F01E64E4262Q35157169-9F565F6F-C299-4E66-B46D-C0A684994CB5Q35191032-2BF9DD6E-EFBA-46A0-9B61-87FBD9A80B52Q35703895-D9CC844D-5173-4F39-A68E-0B53EF0293A1Q38807496-37D3C08F-6042-402B-9FD5-C039DBE1B324Q38939289-F6B47B2F-55D2-4D5A-A813-EFA603F97404Q39279716-8A0AB147-1FC9-4F70-AB32-4CDFFD0A6284Q39297666-789209E1-BA03-4232-B1F9-7B8CFCA930D3Q43565136-BD88D337-7B4E-4144-8015-1F99ED91BB5AQ46493067-DBBE8A70-AF41-48FC-980B-5384E7069757Q51669009-D09E916E-B53F-48DD-9001-C0E38F0ED5B0Q53192816-B874D570-F59C-4B24-B5C1-1004144BFD16Q83202156-CE2B602E-74F2-44C2-AF18-4C587A52F3A4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jeffrey C Crosbie
@ast
Jeffrey C Crosbie
@en
Jeffrey C Crosbie
@es
Jeffrey C Crosbie
@nl
Jeffrey C Crosbie
@sl
type
label
Jeffrey C Crosbie
@ast
Jeffrey C Crosbie
@en
Jeffrey C Crosbie
@es
Jeffrey C Crosbie
@nl
Jeffrey C Crosbie
@sl
prefLabel
Jeffrey C Crosbie
@ast
Jeffrey C Crosbie
@en
Jeffrey C Crosbie
@es
Jeffrey C Crosbie
@nl
Jeffrey C Crosbie
@sl
P1053
F-8465-2010
P106
P21
P31
P3829
P496
0000-0002-8047-5465